M&As this week: Tulip Diagnostics, Mortara Instrument, ForSight VISION4


Under a definitive agreement signed between PerkinElmer and Tulip Diagnostics, the former intends to acquire the latter in order to expand its infectious disease screening capabilities.

PerkinElmer is an imaging and informatics solutions provider, while Tulip is an in-vitro diagnostics developer.

Medical diagnosis device manufacturer, Welch Allyn, intends to acquire Mortara Instrument, a manufacturer of diagnostic cardiology, for a cash consideration of $300m.

"The transaction included an upfront payment from Roche and additional earn-out payments subject to achieving certain development and commercial milestones."

The acquisition, which is expected to be completed on or before 9 April 2017, will strengthen the acquirer company’s business with the addition of the target company’s expertise in diagnostic cardiology and patient monitoring offerings and its ability to integrate with electronic medical record (EMR) systems.

Roche Holdings has completed the acquisition of ForSight VISION4 from ForSight Labs, an ophthalmic incubator based in California, US.

The acquisition enables Roche to expand its exclusive access to ForSight’s Port Delivery System (PDS) technology for long acting delivery of eye therapeutics.

The transaction included an upfront payment from Roche and additional earn-out payments subject to achieving certain development and commercial milestones.

Specialty medical devices manufacturer, Integra LifeSciences, will acquire Derma Sciences for a cash consideration of approximately $204m, and $32 a share for its outstanding shares of series A convertible preferred stock and $48 a share for its series B convertible preferred stock.

Funded by Integra’s existing credit facility, the acquisition will expand the company’s regenerative technology capabilities and also add complementary line of advanced wound care products including amniotic tissue-based products, which can be commercialised using the company’s existing sales channel.